Novartis AG Q1 FY26 Earnings Analysis

- Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competition in the U.S. in the first half of 2026. - Mid-single-digit sales growth is expected in the second half of 2026, leading to a full-year low single-digit growth overall. - The company projects a 5% to 6% compounded annual growth rate (CAGR) in sales from 2025 through 2030, including impacts from generic entries and U.S. MFN agreements. - Growth is anticipated to be driven by priority brands, pipeline assets (e.g., lanalumab, Pluvicto, pelacarsen, Avidity assets), and global expansions such as Leqvio in China. - Cosentyx is forecasted to grow on average at mid-single-digit rates toward an $8 billion peak sales potential. - The cardiovascular portfolio, especially with new oral therapies and pipeline advances, also offers significant growth opportunities.

- Novartis expects **5% to 6% sales CAGR from 2025 to 2030**, despite patent expiries and U.S. MFN impacts. - For **2026**, sales are projected to grow **low single digit**, with **core operating income expected to decline low single digits** due to a tough prior-year base and generic competition. - Core net financial expenses are forecasted around **$1.7 billion in 2026**, higher than 2025, mainly due to funding costs related to the Avidity deal. - Core tax rate is expected to remain around **16.5%**. - Novartis aims to **return to 40% plus core margin by 2029**, supported by strong product launches and productivity programs. - Core EPS grew **17% to $8.98 in 2025** and is expected to continue growth aligned with sales and margin trends. - The company maintains confidence in delivering **mid- to long-term growth** driven by pipeline advances and priority brands.

- Novartis invested over $10 billion in R&D in 2025, an 8% increase compared to the prior year, focusing on strengthening key platforms and pipelines across their four therapeutic areas. - The company completed a $15 billion share buyback program in early July 2025 and launched a new up to $10 billion share buyback program targeted for completion by the end of 2027, with approximately $7.7 billion remaining to be executed. - Novartis announced 4 acquisitions and 10 licensing deals in 2025, focusing on cardiovascular, immunology, neuroscience, and oncology assets, aiming to build and diversify their pipeline. - The anticipated funding costs related to the Avidity Biosciences deal, expected to close in the first half of 2026, will be primarily debt-funded, leading to higher net financial expenses (~$1.7 billion in 2026). - Strategic focus continues on advancing key pipeline assets like ianalumab, pelacarsen, and radioligand therapies, signaling ongoing capital and resource allocation toward late-stage development projects.

- For 2026, Novartis expects core net financial income expenses to be around $1.7 billion, which is higher than 2025 levels. - The increase in financial expenses is largely due to anticipated funding costs related to the Avidity deal. - The Avidity deal is primarily going to be debt funded. - Novartis does not mention any plans for equity fundraising in the provided text. - The company continues to invest in R&D and acquisitions, supported by strong free cash flow generation. - Novartis remains focused on balanced shareholder-friendly capital allocation, including dividends and share buybacks.

The provided transcript does not explicitly mention current or expected orderbook or pending orders details. However, relevant points related to business outlook and growth include: - Novartis expects a 5% to 6% compound annual growth rate (CAGR) in sales from 2025 to 2030. - Anticipation of strong volume growth from priority brands throughout 2026 despite a challenging first half due to prior year base effects. - Full year 2026 sales guidance is low single digit growth. - Pipeline assets including Rhapsido, ianalumab, pelacarsen, and Avidity programs are expected to drive future growth. - The company expects to close the Avidity acquisition by first half 2026, which will impact financials due to development costs. - Continued investment in R&D and launches alongside productivity programs indicates focus on future growth and market capturing. No specific orderbook figures or pending orders were disclosed on page 15 or in closely related sections.